Raptor Pharmaceuticals is a biopharmaceutical company that develops and commercializes life-altering therapeutics that treat rare, debilitating, and often fatal diseases. The company's first product, PROCYSBI, is a delayed-release capsule for the treatment of nephropathic cystinosis, a rare metabolic disorder that affects children and adults. Raptor Pharmaceuticals was acquired by Horizon Pharma in 2016.